Pillstats
Rx only · Capsule, Extended Release · Oral

Disopyramide Phosphate

Brands: Norpace Cr · Disopyramide Phosphate

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US2 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCC01BA03
RxCUI (US)3541
US makers1 labelers
Packages2
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

n/a163247632025 Q12025 Q22025 Q32026 Q1
11
Rx · 2025 Q3
1.2K
Units dispensed
3
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Pfizer Laboratories Div Pfizer Incunknown2SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Dec 2, 2015
    RECALLRecall (Class III): Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-27…

    Failed Dissolution Specification — Recalling firm: Pfizer Inc. — Nationwide

  • May 31, 2013
    RECALLRecall (Class III): Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-27…

    Failed Dissolution Specification — Recalling firm: Pfizer Inc — Nationwide and Puerto Rico